Notably, UBAP2L knockdown resulted in diminished cell viability, decreased maximal inhibitory concentration (IC50) values, and a reduction in both the number and size of colonies in ccRCC cells following sunitinib treatment (Fig. 2C and F-G, S3D, and S3F-G). This evidence concerns the gene UBAP2L and nonpapillary renal cell carcinoma.